Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Can-Fite plummets as novel compound disappoints once again

This article was originally published in Scrip

Executive Summary

The Israeli company Can-Fite BioPharma's Phase II/III trial of its lead product CF101 has failed to meet its primary endpoint in moderate-to-severe plaque psoriasis. This was the second major failure for the product, a first-in-class A3 adenosine receptor agonist, after disappointment in a Phase III trial in dry eye syndrome at the end of 2013, and shares in the firm on the New York Stock Exchange dropped by 60% to close at $2.20 on 30 March.


Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts